Associate Professor of Medicine, University S Fla College of Medicine
Hematology
Dr. Jeffrey Lancet, MD
|
|
Give Review
Jeffrey Lancet practices Hematology. He attended State University of New York Upstate Medical University. He has 1 awards "Regional Top Doctor". Jeffrey Lancet is a published MD. He published 85 publications, including: 'Autotransplantation for relapsed or refractory Hodgkin''s disease: long-term follow-up and analysis of prognostic factors.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Autoimmune Diseases and Myelodysplastic Syndromes.
- Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and Acute myeloid leukemia.
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in Myelodysplastic syndromes.
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory Acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- WT1 vaccination in AML and MDS: A pilot trial with synthetic Analog peptides.
- The molecular basis and clinical significance of genetic mutations identified in Myelodysplastic syndromes.
- A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory Acute myeloid leukemia.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid Leukemia.
- Postremission Therapy in Acute Promyelocytic Leukemia: Room for Improvement?
- Phase II clinical study of erlotinib for treatment of Myelodysplastic syndromes.
- Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreat...
- Novel Therapeutics in Acute Myeloid Leukemia.
- Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous Leukemia: mimicking recurrent B-lymphoid blast crisis.
- Pre-transplant 5-azacitidine in high-risk Myelodysplastic syndrome.
- Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in Acute myeloid leukemia from myelodysplastic syndrome after azanucleosid...
- Acute Myeloid Leukemia, Version 2.2013.
- Poor outcome of patients with Myelodysplastic syndrome after azacitidine treatment failure.
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced Hematologic malignancies.
- Gemtuzumab ozogamicin for treatment of newly diagnosed Acute myeloid leukaemia: a systematic review and meta-analysis.
- Phase I clinical trial of oral rigosertib in patients with Myelodysplastic syndromes.
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic Leukemia.
- Validation of the revised international prognostic scoring System in treated patients with myelodysplastic syndromes.
- Quality of life outcomes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
- The thorny issue of relapsed Acute myeloid leukemia.
- Phase II pilot study of oral dasatinib in patients with higher-risk Myelodysplastic syndrome (MDS) who failed conventional therapy.
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in Myelodysplastic syndrome with chromosome 5q deletion.
- Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.
- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated Acute myeloid leukemia.
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk Myelodysplastic syndromes.
- Concurrence of B-lymphoblastic Leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with Acute myeloid leukemia.
- Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione Analog prodrug, in patients with myelodysplastic syndrome.
- Phase I study for poor-prognosis Lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoiet...
- Treatment of deletion 5q Acute myeloid leukemia with lenalidomide.
- Current status of clinical trials of farnesyltransferase inhibitors.
- Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed Acute leukemias: a phase 1 clinical-laboratory corre...
- Acute myelogenous leukemia and aging. Clinical interactions.
- Autotransplantation for relapsed or refractory Hodgkin''s disease: long-term follow-up and Analysis of prognostic factors.
- Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
- Burkitt''s Leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt''s Leukemia/lymphoma): case report and review of literature.
- Farnesyltransferase inhibitors (FTIs) in myeloid Malignancies.
- Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
- Acute myeloid leukemia clinical practice guidelines in oncology.
- A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory Acute leukemia.
- A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in Cancer.
- Telomere length in Myelodysplastic syndromes.
- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q Acute myeloid leukemia: Southwest Oncology Group Study S0605.
- Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for Acute myelogenou...
- Mixed phenotype Acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
- Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.
- Novel postremission strategies in adults with Acute myeloid leukemia.
- Lenalidomide in Myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
- Outcomes after induction chemotherapy in patients with Acute myeloid leukemia arising from myelodysplastic syndrome.
- First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory Acute...
- A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced Acute leuk...
- Hepatobiliary manifestations of Acute myeloid leukemia.
- Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory Acute lymphocytic leukaemia.
- Salvage chemotherapy regimens for Acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
- Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
- Targeting the process of farynesylation for therapy of Hematologic malignancies.
- Farnesyl transferase inhibitors in myeloid disorders.
- Management of Acute myelogenous leukemia in the elderly.
- Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem Cell transplant recipients.
- Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk Leukemias.
- Farnesyltransferase inhibitors in Hematologic malignancies: new horizons in therapy.
- Farnesyl transferase inhibitors in myeloid Malignancies.
- Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative disea...
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory Acute myeloid leukemia or myelodysplastic syndromes.
- A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in Acute myeloid leukemia.
- Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in Acute myeloid leukemia.
- Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with Acute myelogenous leukemia and poor-risk features.
- A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in Acute myeloid leukemia.
- Development of farnesyltransferase inhibitors for clinical Cancer therapy: focus on hematologic malignancies.
- Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory Acute myelogenous leukemia.
- A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed Acute myeloid leukemia.
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated Acute myelogenous leukemia.
- Development of the farnesyltransferase inhibitor tipifarnib for therapy of Hematologic malignancies.
- Microarray analysis reveals genetic pathways modulated by tipifarnib in Acute myeloid leukemia.
- Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory Acute myeloid leukemia.
- Therapy for older AML patients: the role of novel agents and allogeneic stem Cell transplant.
- Tipifarnib in the treatment of newly diagnosed Acute myelogenous leukemia.
- 5-Azacitidine for myelodysplasia before allogeneic hematopoietic Cell transplantation.
Schools
SUNY Upstate Medical University Syracuse
Strong Memorial Hospital
St Mary39s Hospital
Strong Meml Hospital University Rochester
Ba University Of RochesterBiology Psychology
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Basal Cell Carcinoma
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Rochester -
State University of New York Upstate Medical University
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1831110337 | |
| NPPES Provider LastName | LANCET | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 225.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831110337 |
| Last Name Of The Provider | LANCET |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
Dr. Ron D. Schiff, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Shohreh I. Iravani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin Djulbegovic, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Egberto J. Zayas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce O. Hough, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William R. Dinwoodie, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph Pidala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad O. Hussaini, MD |
|
|
Dr. Mojdeh Naghashpour, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ragini Kudchadkar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William S. Dalton, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bennett W. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Javier A. Pinilla-Ibarz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Estrella M. Carballido, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minesh D. Patel, MD |
|
|
Dr. Melvyn S. Tockman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vishakha A. Kale, MD
This Doctor is OpenDoctor Recommended.
|